Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance in people hospitalized for acute heart failure who have been stabilized.

Boehringer Ingelheim and Eli Lilly and Company announced the initiation of EMPULSE, the sixth phase III study in the Jardiance (empagliflozin) heart failure program. The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized.

The study will include participants both with and without type 2 diabetes. Heart failure contributes to one in nine deaths and is a leading cause of hospitalization in the U.S., yet there are limited treatment options for people living with this debilitating disease. Outcomes for patients after they have been hospitalized for heart failure are poor, with a 15 percent mortality and 30 percent readmission rate within 60 to 90 days of discharge from the hospital. Initiating treatment in the hospital is one of the best predictors of long-term improved prognosis and patient treatment adherence. The EMPULSE study aims to understand whether Jardiance has the potential to improve outcomes in this population.